PT  - JOURNAL ARTICLE
AU  - Gandotra, Neeru
AU  - Tikhonova, Irina
AU  - Cheemarla, Nagarjuna R.
AU  - Knight, James
AU  - Foxman, Ellen
AU  - Giraldez, Antonio
AU  - Shen, Peidong
AU  - Bilguvar, Kaya
AU  - Scharfe, Curt
TI  - A two-pronged approach for rapid and high-throughput SARS-CoV-2 nucleic acid testing
AID  - 10.1101/2020.12.04.20234450
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.04.20234450
4099  - http://medrxiv.org/content/early/2020/12/07/2020.12.04.20234450.short
4100  - http://medrxiv.org/content/early/2020/12/07/2020.12.04.20234450.full
AB  - Improved molecular screening and diagnostic tools are needed to substantially increase SARS-CoV-2 testing capacity and throughput while reducing the time to receive test results. Here we developed multiplex reverse transcriptase polymerase chain reaction (m-RT-PCR) for detection of SARS-CoV-2 using rapid DNA electrophoresis and alternatively using multiplex viral sequencing (mVseq). For RNA specimens extracted from nasopharyngeal (NP) swabs in viral transport media (VTM), our assays achieved a sensitivity for SARS-CoV-2 detection corresponding to cycle threshold (Ct) of 37.2 based on testing of these specimens using quantitative reverse transcription PCR (RT-qPCR). For NP swab-VTM specimens without prior RNA extraction, sensitivity was reduced to Ct of 31.6, which was due to lower concentration of SARS-CoV-2 genome copies in VTM compared to RNA-extracted samples. Assay turnaround time was 60 minutes using rapid gel electrophoresis, 90 minutes using Agilent Bioanalyzer, and 24-48 hours using Illumina sequencing, the latter of which required a second PCR to produce a sequence-ready library using m-RT-PCR products as the template. Our assays can be employed for high-throughput sequencing-based detection of SARS-CoV-2 directly from a clinical specimen without RNA isolation, while ease-of-use and low cost of the electrophoresis-based readout enables screening, particularly in resource-constrained settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by institutional funds at Yale University. No external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Yale Institutional Review Board determined this study to be not human subjects research (IRB Protocol #2000029556).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request